Orchid's Q1 revenues backed up by supplies to Hospira
This article was originally published in Scrip
Executive Summary
Orchid Chemicals and Pharmaceuticals reported higher revenues of Rs3.31 billion ($70.2 million) for the first quarter ended 30 June 2010, supported by supplies of active pharmaceutical ingredients (APIs) to Hospira of the US and other operating income, mainly settlement and milestone payments. Revenues in the first quarter of the previous fiscal year were Rs3.09 billion.